Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent

Cardiovascular Drugs and Therapy

Volumn 10, Issue SUPPL. 1, 1996, Pages 275-282

  Ernsberger, Paul ^a,b   Koletsky, Richard J ^a   Collins, Laura A ^a   Bedol, David ^a  

^a St Luke's Hospital Cleveland   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Glomerulosclerosis; Hyperlipidemia; Imidazoline receptors; Insulin resistance; Moxonidine; Obese spontaneously hypertensive rats; SHROB

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; INSULIN; MOXONIDINE; TRIACYLGLYCEROL;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DIET; FEMALE; FOOD INTAKE; GANGLION BLOCK; GLUCOSE TOLERANCE; HYPERTENSION; INSULIN BLOOD LEVEL; KIDNEY INJURY; MALE; NONHUMAN; OBESITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RECESSIVE INHERITANCE; SALT INTAKE; SALT LOADING; SPONTANEOUSLY HYPERTENSIVE RAT; SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; EATING; FEMALE; GLUCOSE TOLERANCE TEST; HYPERTENSION; IMIDAZOLES; INSULIN; LIPIDS; MALE; OBESITY; PROTEINURIA; RATS; RATS, INBRED SHR; SENSITIVITY AND SPECIFICITY; SODIUM CHLORIDE; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 0030013287     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00120497     Document Type: Conference Paper

References (43)

1. Kjeldsen SE, Schork NJ, Leren P, Eide IK. Arterial plasma norepinephrine correlates to blood pressure in middle-aged men with sustained essential hypertension. Am Heart J 1989;118:775-781.
2. Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension of Tecumseh, Michigan. J Hypertens 1991;9:77-84.
3. Landsberg L. Pathophysiology of obesity-related hypertension: Role of insulin and the sympathetic nervous system. J Cardiovasc Pharmacol 1994;23(Suppl 1):S1-S8.
4. Bray GA. Obesity, a disorder of nutrient partitioning: The MONA LISA hypothesis. J Nutr 1991;121:1146-1162.
5. Ernsberger P, Koletsky RJ, Baskin JS, Foley M. Refeeding hypertension in obese spontaneously hypertensive rats. Hypertension 1994;24:699-705.
6. Koletsky RJ, Boccia J, Ernsberger P. Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clin Exp Pharmacol Physiol 1995;22:S254-S256.
7. Julius S. The defense reaction: A common denominator of coronary risk and blood pressure in neurogenic hypertension. Clin Exp Hypertens 1995;17:375-386.
8. DiBona GF. Sympathetic neural control of the kidney in hypertension. Hypertension 1992;19(Suppl I):I28-I35.
9. Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989;76: 109-117.
10. Daly PA, Landsberg L. Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system. Diabet Care 1991;14:240-248.
11. Zavaroni I, Bonini L, Fantuzzi M, Dall'aglio E, Passeri M, Reaven GM. Hyperinsulinaemia, obesity, and syndrome X. J Intern Med 1994;235:51-56.
12. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993;44:121-131.
13. Koletsky RJ, Collins LA, Bedol D, Ernsberger P. Obese SHR as a model of human syndrome X. FASEB J 1995;9: A187.
14. Koletsky RJ, Ernsberger P. Obese SHR (Koletsky Rat): A model for the interactions between obesity and hypertension. In: Sassard J, ed. Genetic Hypertension. London: John Libbey, 1992:373-375.
15. Ernsberger P, Koletsky RJ, Collins LA, Douglas JG. Renal angiotensin receptor mapping in obese spontaneously hypertensive rats. Hypertension 1993;21:1039-1045.
16. Koletsky S. Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 1975; 80:129-142.
17. Ernsberger P, Koletsky RJ, Collins LA. Lethal consequences of a high salt diet in obese SHR. Hypertension 1994;24:376.
18. Koletsky RJ, Boccia J, Ernsberger P. Acceleration of renal disease in obese SHR by exacerbation of hypertension. Clin Exp Pharmacol Physiol 1995;22:S254-S256.
19. Nakamura Y, Calhoun DA, Chen Y-F, Wyss JM, Oparil S. Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats. Hypertension 1993;22:285-291.
20. Di Nicolantonio R, Silvapulle MJ. Blood pressure, salt appetite and mortality of genetically hypertensive and normotensive rats maintained on high and low salt diets from weaning, Clin Exp Pharmacol Physiol 1988;15:741-751.
21. 1-Imidazoline receptors: Definition, characterization, distribution and transmembrane signaling. Ann NY Acad Sci 1995;763: 22-42.
22. Peterson GL. A simplification of the protein assay method of Lowry et al, which is more generally applicable. Anal Biochem 1977;83:346-356.
23. Neuringer JR, Brenner BM. Hemodynamic theory of progressive renal disease: A 10-year update in brief review. Am J Kidney Dis 1993;22:98-104.
24. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats: A micromophometric study. Am J Hypertens 1992;5:437-443.
25. Metcalf P, Baker J, Scott A, Wild C, Scragg R, Dryson E. Albuminuria in people at least 40 years old: Effect of obesity, hypertension, and hyperlipidemia. Clin Chem 1992;38: 1802-1808.
26. Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991;39:S35-S40.
27. Kamanna VS, Kirschenbaum MA. Association between very-low-density lipoprotein and glomerular injury in obese Zucker rats. Am J Nephrol 1993;13:53-58.
28. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993;22:83-89.
29. Koletsky S, Puterman DI. Effect of low calorie diet on the hyperlipidemia, hypertension, and life span of genetically obese rats. Proc Soc Exp Biol Med 1976;151:368-371.
30. Goldstein DJ, Potvin JH. Long-term weight loss: The effect of pharmacologic agents. Am J Clin Nutr 1994;60:647-657.
31. Bremer JM, Scott RS, Lintott CJ. Defenfluramine reduces cardiovascular risk factors. Int J Obes 1994;18:199-205.
32. Fisler JS, Underberger SJ, York DA, Bray GA. d-Fenfluramine in a rat model of dietary fat-induced obesity. Pharmacol Biochem Behav 1993;45:487-493.
33. Kaan EC, Brückner R, Frohly P, Tulp M, Schäfer SG, Ziegler D. Effects of agmatine and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995;5(Suppl 1):19-27.
34. DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia 1981; 21:165-171.
35. Hall JE, Coleman TG, Mizelle HL. Does chronic hyperinsulinemia cause hypertension? Am J Hypertens 1989;2:171-173.
36. Bouchard C, Tremblay A, Després J-P, et al. The response to long-term overfeeding in identical twins. N Engl J Med 1990;322:1477-1482.
37. Troisi RJ, Weiss ST, Parker DR. Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991;17:669-677.
38. 1-imidazoline sites. J Pharmacol Exp Ther 1993;264:172-182.
39. Ernsberger P, Elliott HL, Weimann H-J, et al. Moxonidine: A second-generation central antihypertensive agent. Cardiovasc Drug Rev 1993;11:411-431.
40. 1-imidazoline agonist. Cardiovasc Drugs Ther 1994;8(Suppl 1):27-41.
41. 2-adrenoceptor agonists. J Pharmacol Exp Ther 1984;228:168-173.
42. Tsujii S, Bray GA. Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists. Brain Res 1992;587:226-232.
43. McCabe JT, DeBellis M, Leibowitz SF. Clonidine-induced feeding: Analysis of central sites of action and fiber projections mediating this response. Brain Res 1984;309:85-104.